

**Supplementary Table 1.** Baseline characteristics of the study participants

Characteristic	Value
Age, yr	51.1 ± 10.6
Female sex	43 (41.3)
Duration of diabetes, yr	11.7 ± 7.1
Hypertension	70 (67.3)
Dyslipidemia	101 (97.1)
Diabetes complications	
Retinopathy	50 (48.1)
Nephropathy	52 (50.0)
Neuropathy	29 (27.9)
Cardiovascular disease	18 (17.3)
Cerebrovascular disease	2 (1.9)
Peripheral vascular disease	2 (1.9)
Heart failure	2 (1.9)
Previous insulin user	27 (26.0)
Use of concomitant diabetes drugs	
Metformin	102 (98.1)
Sulfonylurea	85 (81.7)
Thiazolidinedione	2 (1.9)
Insulin	11 (10.6)
Combination sequence	
SGLT2 inhibitor first	48 (46.2)
GLP-1RA first	48 (46.2)
Simultaneous addition	8 (7.7)
SGLT2 inhibitor type	
Dapagliflozin	71 (68.3)
Empagliflozin	33 (31.7)
Dulaglutide dose, mg	
0.75	30 (28.8)
1.5	74 (71.2)

Values are presented as mean ± standard deviation or number (%). SGLT2, sodium-glucose cotransporter 2; GLP-1RA, glucagon-like peptide-1 receptor agonist.